Article citationsMore>>
Baselga, J., Cortés, J., Kim, S.B., Im, S.A., Hegg, R., Im, Y.H., Roman, L., Pedrini, J.L., Pienkowski, T., Knott, A., Clark, E., Benyunes, M.C., Ross, G. and Swain, S.M. for the CLEOPATRA Study Group (2012) Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer. New England Journal of Medicine, 366, 109-119.
https://doi.org/10.1056/NEJMoa1113216
has been cited by the following article:
-
TITLE:
Impressive Objective Response to Nab-Paclitaxel plus Trastuzumab as Fifth Line Therapy in an Elderly HER-2 Positive Breast Cancer Patient
AUTHORS:
Maria Rosaria Valerio, Chiara Ancona, Antonella Marchese, Vittorio Gebbia
KEYWORDS:
Nab-Paclitaxel, Trastuzumab, HER-2, Metastasis, Breast Cancer
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.8 No.11,
November
16,
2017
ABSTRACT: Background: Agent targeting HER-2 pathway
plus chemotherapy has represented a major
progress in the management of patients with breast cancer. However, the role of late-line treatment in heavily
pretreated patients is still largely unclear. In the last decade, nab-paclitaxel has shown significant activity
and good toxicity profile in metastatic breast cancer. Case Presentation: We report the case of a 76-year-old Caucasian woman
with metastatic HER-2 positive ductal infiltrating breast carcinoma treated
with a combination of weekly nab-paclitaxel and trastuzumab as fifth-line
therapy. She had previously received first-line paclitaxel and trastuzumab,
second-line vinorelbine and trastuzumab, third-line TDM1 and fourth-line oral
capecitabine and lapatinib. Clinical and radiological staging showed
progression at bone, skin and soft-tissue. The patient received weekly
nab-paclitaxel plus trastuzumab. Massive objective response was clinically and
PET documented which lasted 8 months. Tolerance to treatment was fairly good as
well as cardiac safety. Conclusion: To the best of our knowledge, this
is the first reported case of efficacy of nab-paclitaxel in combination with
trastuzumab as fifth-line of treatment in a patient with metastatic HER-2
positive breast cancer.
Related Articles:
-
Masahiro Kitada, Shunsuke Yasuda, Masahiro Abe, Nana Yoshida, Satoshi Okazaki, Kei Ishibashi
-
Jaana Korpela, Pekka Mali, Anne Kaljonen, Eeva Salminen
-
Toshikazu Moriwaki, Tetsuya Eto, Akihito Tsuji, Nobushige Kakinoki, Mitsuo Shimada, Takashi Maeba, Hiroaki Hatano, Ikuo Takahashi, Hiroyasu Ishida, Kazuho Ikeda, Yoshiaki Bando, Ichinosuke Hyodo
-
Christian Willemse, Nader Soltani, Brendan Metzger, David C. Hooker, Amit J. Jhala, Darren E. Robinson, Peter H. Sikkema
-
Yasutake Uchima, Naoki Aomatsu, Gen Tsujio, Takehiko Iwauchi, Shinji Matsutani, Hiroto Tanaka, Hironari Miyamoto, Takuma Okada, Shigeaki Kurihara, Toshiki Hirakawa, Keiichiro Hirata, Junya Morimoto, Shigehito Yamagata, Kazuhiro Takeuchi